- Home
- NCNA vs CWD Comparison
NCNA vs CWD Comparison
Compare NCNA & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCNA | CWD |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 10.0M |
| IPO Year | 2017 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NCNA | CWD |
|---|---|---|
| Price | $2.01 | $1.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.4K | ★ 37.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,119,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.03 | $0.20 |
| 52 Week High | $10.00 | $46.21 |
Technical Indicators
Market Signals| Indicator | NCNA | CWD |
|---|---|---|
| Relative Strength Index (RSI) | 38.45 | 58.90 |
| Support Level | $0.05 | $1.11 |
| Resistance Level | $2.27 | $1.54 |
| Average True Range (ATR) | 0.16 | 0.10 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 27.03 | 73.23 |
Price Performance
Historical ComparisonAbout NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.